0

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Proguanil Hydrochloride

Gerlinde F Plöger, Bertil Abrahamsson, Rodrigo Cristofoletti, Dirk W Groot, Peter Langguth, Mehul U Mehta, Alan Parr, James E Polli, Vinod P Shah, Tomokazu Tajiri, Jennifer B Dressman

J Pharm Sci. 2018 Jul;107(7):1761-1772.

PMID: 29571740

Abstract:

Literature data relevant to the decision to waive in vivo bioequivalence testing for the approval of generic immediate release solid oral dosage forms of proguanil hydrochloride are reviewed. To elucidate the Biopharmaceutics Classification System (BCS) classification, experimental solubility and dissolution studies were also carried out. The antimalarial proguanil hydrochloride, effective via the parent compound proguanil and the metabolite cycloguanil, is not considered to be a narrow therapeutic index drug. Proguanil hydrochloride salt was shown to be highly soluble according to the U.S. Food and Drug Administration, World Health Organization, and European Medicines Agency guidelines, but data for permeability are inconclusive. Therefore, proguanil hydrochloride is conservatively classified as a BCS class 3 substance. In view of this information and the assessment of risks associated with a false positive decision, a BCS-based biowaiver approval procedure can be recommended for orally administered solid immediate release products containing proguanil hydrochloride, provided well-known excipients are used in usual amounts and provided the in vitro dissolution of the test and reference products is very rapid (85% or more are dissolved in 15 min at pH 1.2, 4.5, and 6.8) and is performed according to the current requirements for BCS-based biowaivers.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP637321-A Proguanil hydrochloride Proguanil hydrochloride 637-32-1 Price
qrcode